LSD1 is important for the differentiation block in MLL variants of AML; preclinical studies have shown that LSD1 inhibitors induce monocytic differentiation with morphological signs together with decreased expression of the CD34 stem cell marker and increased expression of CD14, CD36 and CD86 [181,182]. Here, CD14 is linked to acute myeloid leukemia.